Over the past five years, Waters Corporation has invested approximately 10% of its product sales in research and development, resulting in a 25% increase in new product introductions and a revitalized innovation pipeline. The company now has roughly 170,000 of its analytical instruments installed across regulated and high-volume laboratories worldwide, up from 135,000 installations in 2019. This expansion has contributed to a 12% compound annual growth rate in core chromatography and mass spectrometry revenues, reinforcing Waters’ position as a market leader in analytical life-science tools.

In late 2023, Waters completed the acquisition of BD’s Bioscience and Diagnostics business, adding over $400 million in annual revenue and expanding its addressable market in cell analysis and diagnostic testing. The deal brings 300 new customer relationships in clinical and research settings and integrates BD’s flow cytometry and immunoassay platforms into Waters’ existing portfolio. Management expects cost synergies of $25 million by year three and anticipates the acquisition will contribute 3–4 percentage points to overall revenue growth in 2025.

Looking ahead, CEO Udit Batra highlighted plans to deliver 7–9% annual organic growth over the next three years, driven by geographic expansion in Asia-Pacific and the rollout of two next-generation mass spectrometers in 2026. Waters reaffirmed its target of mid-teens adjusted operating margin by fiscal 2027, supported by ongoing efficiency programs and disciplined capital allocation. The company also signaled potential bolt-on acquisitions in adjacent genomics and cell-therapy analytics, aiming to sustain its track record of 10% total shareholder return over the past decade.